PHI is active in medical technology and develops both hardware and software for quantitative analysis of living cell cultures. The HoloMonitor® products are based on non-invasive QPI technology that collects data on cell quality and are sold globally through distributors with a focus on preclinical cancer research, stem cell research and drug development. Going forward, PHI focuses on developing its products for the clinical market and in regenerative medicine. PHI has offices in Lund, Boston, and Winston-Salem.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Altium S.A | 41,62 | 41,62 | 2025-03-27 |
| Avanza Pension | 4,66 | 4,66 | 2025-03-27 |
| Nordnet Pensionsförsäkring | 2,19 | 2,19 | 2025-03-27 |
| Peter Egelberg | 2,08 | 2,08 | 2025-03-27 |
| Felix Leibnitz | 1,00 | 1,00 | 2025-03-27 |
| Fenja Capital Partners A/S | 0,97 | 0,97 | 2025-03-27 |
| Per Vasilis | 0,86 | 0,86 | 2025-03-27 |
| Mirjana Stavrov Jasim | 0,83 | 0,83 | 2025-03-27 |
| Claes Frösslund | 0,78 | 0,78 | 2025-03-27 |
| Leland Foster | 0,66 | 0,66 | 2025-03-27 |
